SHANGHAI, April 9, 2022 — Shanghai Henlius Biotech, Inc. (2696.HK) says the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer. This is the first such designation granted to HANSIZHUANG. The ODD granted by the FDA